Assessment  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
Tumor  ||| S:14 E:20 ||| NNP
Necrosis  ||| S:20 E:29 ||| NNP
Factor  ||| S:29 E:36 ||| NNP
alpha  ||| S:36 E:42 ||| NN
gene  ||| S:42 E:47 ||| NN
expression  ||| S:47 E:58 ||| NN
profile  ||| S:58 E:66 ||| NN
in  ||| S:66 E:69 ||| IN
selected  ||| S:69 E:78 ||| JJ
structures  ||| S:78 E:89 ||| NNS
of  ||| S:89 E:92 ||| IN
middle  ||| S:92 E:99 ||| JJ
ear  ||| S:99 E:103 ||| NN
in  ||| S:103 E:106 ||| IN
patients  ||| S:106 E:115 ||| NNS
with  ||| S:115 E:120 ||| IN
tympanosclerosis  ||| S:120 E:137 ||| JJ
Tympanosclerosis  ||| S:137 E:154 ||| NNP
is  ||| S:154 E:157 ||| VBZ
a  ||| S:157 E:159 ||| DT
middle  ||| S:159 E:166 ||| JJ
ear  ||| S:166 E:170 ||| NN
disease  ||| S:170 E:178 ||| NN
located  ||| S:178 E:186 ||| VBN
in  ||| S:186 E:189 ||| IN
submucous  ||| S:189 E:199 ||| JJ
membrane ||| S:199 E:207 ||| NN
.  ||| S:207 E:209 ||| .
It  ||| S:209 E:212 ||| PRP
leads  ||| S:212 E:218 ||| VBZ
to  ||| S:218 E:221 ||| TO
the  ||| S:221 E:225 ||| DT
tympanic  ||| S:225 E:234 ||| JJ
membrane  ||| S:234 E:243 ||| NN
and  ||| S:243 E:247 ||| CC
ear  ||| S:247 E:251 ||| JJ
ossicles  ||| S:251 E:260 ||| JJ
fixation  ||| S:260 E:269 ||| NN
which  ||| S:269 E:275 ||| WDT
results  ||| S:275 E:283 ||| NNS
in  ||| S:283 E:286 ||| IN
severe  ||| S:286 E:293 ||| JJ
conductive  ||| S:293 E:304 ||| JJ
hearing  ||| S:304 E:312 ||| NN
impairment ||| S:312 E:322 ||| NN
.  ||| S:322 E:324 ||| .
The  ||| S:324 E:328 ||| DT
etiology  ||| S:328 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
tympanosclerosis  ||| S:340 E:357 ||| NN
remains  ||| S:357 E:365 ||| VBZ
unclear ||| S:365 E:372 ||| JJ
.  ||| S:372 E:374 ||| .
Cytokines  ||| S:374 E:384 ||| NNS
play  ||| S:384 E:389 ||| VBP
very  ||| S:389 E:394 ||| RB
important  ||| S:394 E:404 ||| JJ
role  ||| S:404 E:409 ||| NN
in  ||| S:409 E:412 ||| IN
development  ||| S:412 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
tympanosclerosis ||| S:427 E:443 ||| NN
.  ||| S:443 E:445 ||| .
The  ||| S:445 E:449 ||| DT
research  ||| S:449 E:458 ||| NN
aimed  ||| S:458 E:464 ||| VBN
to  ||| S:464 E:467 ||| TO
assess  ||| S:467 E:474 ||| VB
gene  ||| S:474 E:479 ||| NN
expression  ||| S:479 E:490 ||| NN
level  ||| S:490 E:496 ||| NN
of  ||| S:496 E:499 ||| IN
pro  ||| S:499 E:503 ||| FW
inflammatory  ||| S:503 E:516 ||| FW
cytokine  ||| S:516 E:525 ||| FW
TNF-α  ||| S:525 E:531 ||| FW
in  ||| S:531 E:534 ||| IN
selected  ||| S:534 E:543 ||| JJ
structures  ||| S:543 E:554 ||| NNS
of  ||| S:554 E:557 ||| IN
middle  ||| S:557 E:564 ||| JJ
ear  ||| S:564 E:568 ||| NN
in  ||| S:568 E:571 ||| IN
patients  ||| S:571 E:580 ||| NNS
with  ||| S:580 E:585 ||| IN
chronic  ||| S:585 E:593 ||| JJ
otitis  ||| S:593 E:600 ||| JJ
media  ||| S:600 E:606 ||| NNS
with  ||| S:606 E:611 ||| IN
tympanosclerosis ||| S:611 E:627 ||| NN
.  ||| S:627 E:629 ||| .
The  ||| S:629 E:633 ||| DT
research  ||| S:633 E:642 ||| NN
was  ||| S:642 E:646 ||| VBD
performed  ||| S:646 E:656 ||| VBN
on  ||| S:656 E:659 ||| IN
middle  ||| S:659 E:666 ||| JJ
ear  ||| S:666 E:670 ||| NN
tissues  ||| S:670 E:678 ||| NNS
with  ||| S:678 E:683 ||| IN
tympanosclerosis  ||| S:683 E:700 ||| VBG
achieved  ||| S:700 E:709 ||| VBN
from  ||| S:709 E:714 ||| IN
30  ||| S:714 E:717 ||| CD
patients  ||| S:717 E:726 ||| NNS
operated  ||| S:726 E:735 ||| VBD
on  ||| S:735 E:738 ||| RP
in  ||| S:738 E:741 ||| IN
the  ||| S:741 E:745 ||| DT
Otolaryngology  ||| S:745 E:760 ||| NNP
Department  ||| S:760 E:771 ||| NNP
of  ||| S:771 E:774 ||| IN
the  ||| S:774 E:778 ||| DT
Medical  ||| S:778 E:786 ||| NNP
University  ||| S:786 E:797 ||| NNP
of  ||| S:797 E:800 ||| IN
Gdańsk ||| S:800 E:806 ||| NNP
.  ||| S:806 E:808 ||| .
The  ||| S:808 E:812 ||| DT
control  ||| S:812 E:820 ||| NN
group  ||| S:820 E:826 ||| NN
was  ||| S:826 E:830 ||| VBD
formed  ||| S:830 E:837 ||| VBN
by  ||| S:837 E:840 ||| IN
tympanic  ||| S:840 E:849 ||| NNS
membranes  ||| S:849 E:859 ||| VBP
sampled  ||| S:859 E:867 ||| VBN
from  ||| S:867 E:872 ||| IN
17  ||| S:872 E:875 ||| CD
corpses  ||| S:875 E:883 ||| NN
of  ||| S:883 E:886 ||| IN
patients  ||| S:886 E:895 ||| NNS
who  ||| S:895 E:899 ||| WP
died  ||| S:899 E:904 ||| VBD
suddenly ||| S:904 E:912 ||| RB
.  ||| S:912 E:914 ||| .
Advancement  ||| S:914 E:926 ||| NNP
of  ||| S:926 E:929 ||| IN
tympanosclerotic  ||| S:929 E:946 ||| JJ
changes  ||| S:946 E:954 ||| NNS
were  ||| S:954 E:959 ||| VBD
grouped  ||| S:959 E:967 ||| VBN
based  ||| S:967 E:973 ||| VBN
on  ||| S:973 E:976 ||| IN
Tos  ||| S:976 E:980 ||| NNP
classification ||| S:980 E:994 ||| NN
.  ||| S:994 E:996 ||| .
The  ||| S:996 E:1000 ||| DT
TNF-α  ||| S:1000 E:1006 ||| JJ
gene  ||| S:1006 E:1011 ||| NN
expression  ||| S:1011 E:1022 ||| NN
level  ||| S:1022 E:1028 ||| NN
was  ||| S:1028 E:1032 ||| VBD
measured  ||| S:1032 E:1041 ||| VBN
by  ||| S:1041 E:1044 ||| IN
real  ||| S:1044 E:1049 ||| JJ
time  ||| S:1049 E:1054 ||| NN
PCR  ||| S:1054 E:1058 ||| NN
with  ||| S:1058 E:1063 ||| IN
specific  ||| S:1063 E:1072 ||| JJ
hydrolysed  ||| S:1072 E:1083 ||| JJ
probes  ||| S:1083 E:1090 ||| NNS
( ||| S:1090 E:1091 ||| -LRB-
TaqMan ||| S:1091 E:1097 ||| NNP
) ||| S:1097 E:1098 ||| -RRB-
.  ||| S:1098 E:1100 ||| .
The  ||| S:1100 E:1104 ||| DT
gene  ||| S:1104 E:1109 ||| NN
expression  ||| S:1109 E:1120 ||| NN
level  ||| S:1120 E:1126 ||| NN
for  ||| S:1126 E:1130 ||| IN
TNF-α  ||| S:1130 E:1136 ||| NNP
was  ||| S:1136 E:1140 ||| VBD
correlated  ||| S:1140 E:1151 ||| VBN
with  ||| S:1151 E:1156 ||| IN
clinical  ||| S:1156 E:1165 ||| JJ
classification  ||| S:1165 E:1180 ||| NN
of  ||| S:1180 E:1183 ||| IN
tympanosclerosis ||| S:1183 E:1199 ||| NN
.  ||| S:1199 E:1201 ||| .
The  ||| S:1201 E:1205 ||| DT
level  ||| S:1205 E:1211 ||| NN
of  ||| S:1211 E:1214 ||| IN
gene  ||| S:1214 E:1219 ||| NN
profile  ||| S:1219 E:1227 ||| NN
expression  ||| S:1227 E:1238 ||| NN
for  ||| S:1238 E:1242 ||| IN
TNF-α  ||| S:1242 E:1248 ||| JJ
in  ||| S:1248 E:1251 ||| IN
selected  ||| S:1251 E:1260 ||| JJ
structures  ||| S:1260 E:1271 ||| NNS
of  ||| S:1271 E:1274 ||| IN
the  ||| S:1274 E:1278 ||| DT
middle  ||| S:1278 E:1285 ||| JJ
ear  ||| S:1285 E:1289 ||| NN
with  ||| S:1289 E:1294 ||| IN
tympanosclerosis  ||| S:1294 E:1311 ||| NN
was  ||| S:1311 E:1315 ||| VBD
statistically  ||| S:1315 E:1329 ||| RB
significant ||| S:1329 E:1340 ||| JJ
,  ||| S:1340 E:1342 ||| ,
higher  ||| S:1342 E:1349 ||| JJR
in  ||| S:1349 E:1352 ||| IN
comparison  ||| S:1352 E:1363 ||| NN
with  ||| S:1363 E:1368 ||| IN
the  ||| S:1368 E:1372 ||| DT
control  ||| S:1372 E:1380 ||| NN
group ||| S:1380 E:1385 ||| NN
.  ||| S:1385 E:1387 ||| .
The  ||| S:1387 E:1391 ||| DT
highest  ||| S:1391 E:1399 ||| JJS
level  ||| S:1399 E:1405 ||| NN
of  ||| S:1405 E:1408 ||| IN
expression  ||| S:1408 E:1419 ||| NN
was  ||| S:1419 E:1423 ||| VBD
observed  ||| S:1423 E:1432 ||| VBN
in  ||| S:1432 E:1435 ||| IN
group  ||| S:1435 E:1441 ||| NN
two  ||| S:1441 E:1445 ||| CD
which  ||| S:1445 E:1451 ||| WDT
is  ||| S:1451 E:1454 ||| VBZ
relevant  ||| S:1454 E:1463 ||| JJ
to  ||| S:1463 E:1466 ||| TO
more  ||| S:1466 E:1471 ||| RBR
advanced  ||| S:1471 E:1480 ||| JJ
tympanosclerosis ||| S:1480 E:1496 ||| NN
.  ||| S:1496 E:1498 ||| .
Tympanosclerosis  ||| S:1498 E:1515 ||| NNP
is  ||| S:1515 E:1518 ||| VBZ
a  ||| S:1518 E:1520 ||| DT
result  ||| S:1520 E:1527 ||| NN
of  ||| S:1527 E:1530 ||| IN
constant  ||| S:1530 E:1539 ||| JJ
inflammatory  ||| S:1539 E:1552 ||| JJ
process  ||| S:1552 E:1560 ||| NN
and  ||| S:1560 E:1564 ||| CC
it  ||| S:1564 E:1567 ||| PRP
is  ||| S:1567 E:1570 ||| VBZ
modulated  ||| S:1570 E:1580 ||| VBN
by  ||| S:1580 E:1583 ||| IN
cytokines  ||| S:1583 E:1593 ||| NNS
including  ||| S:1593 E:1603 ||| VBG
TNF-α ||| S:1603 E:1608 ||| JJ
.  ||| S:1608 E:1610 ||| .
The  ||| S:1610 E:1614 ||| DT
positive  ||| S:1614 E:1623 ||| JJ
correlation  ||| S:1623 E:1635 ||| NN
between  ||| S:1635 E:1643 ||| IN
gene  ||| S:1643 E:1648 ||| NN
expression  ||| S:1648 E:1659 ||| NN
level  ||| S:1659 E:1665 ||| NN
of  ||| S:1665 E:1668 ||| IN
TNF-α  ||| S:1668 E:1674 ||| JJ
and  ||| S:1674 E:1678 ||| CC
tympanosclerosis  ||| S:1678 E:1695 ||| NNS
could  ||| S:1695 E:1701 ||| MD
in  ||| S:1701 E:1704 ||| IN
the  ||| S:1704 E:1708 ||| DT
future  ||| S:1708 E:1715 ||| JJ
contribute  ||| S:1715 E:1726 ||| NN
to  ||| S:1726 E:1729 ||| TO
antiinflammatory ||| S:1729 E:1745 ||| VB
,  ||| S:1745 E:1747 ||| ,
medical  ||| S:1747 E:1755 ||| JJ
treatment  ||| S:1755 E:1765 ||| NN
of  ||| S:1765 E:1768 ||| IN
tympanosclerosis ||| S:1768 E:1784 ||| NN
.  ||| S:1784 E:1786 ||| .
